PEG-ing the Path to Regularity for Kids With Constipation Woes, Muout, Docvidya, Pediatrics, Pediatric functional constipation, Paediatrician, PEG, Bowel movements.
More than 40% children with functional constipation have <3 bowel movements per week.2
The primary goal in treating functional constipation is to establish regular bowel movements, ideally once daily, with the passage of soft stools and without difficulty.3
Laxatives are commonly prescribed for disimpaction and maintenance therapy.3,4
A randomized, single-blinded clinical trial evaluated pediatric patients suffering functional constipation to compare the efficacy of PEG with lactulose.1
PEG for fecal disimpaction and as maintenance therapy for 16 weeks.
Rectal enema for 2 days for stool disimpaction, followed by lactulose±senna.
More patients treated with PEG demonstrate increase in stool frequency compared to lactulose (p < 0.05).4
PEG offers a better choice compared to lactulose in the management of pediatric functional constipation.4
Abbreviation ▼
PEG: Polyethylene glycol.
References ▼
1. Pashankar DS, Loening-Baucke V, Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med. 2003;157(7):661–664. 2. Afzal NA, Tighe MP, Thomson MA. Constipation in children. Ital J Pediatr. 2011;37:28. 3. Tran DL, Sintusek P. Functional constipation in children: What physicians should know. World J Gastroenterol. 2023;29(8):1261–1288. 4. Bastaoros O, Gad MA, Eskander AE, et al. The use of polyethylene glycol as a maintenance treatment of functional constipation in children living in Egypt. Egyptian Pediatr Assoc Gazette. 2023;71:67.
LMRC Code: GGI-CO-A1-AQS-300024228-ELC-H24-0882
For the use of a Registered Medical Practitioner, Hospital or Laboratory only.
Disclaimer
The images are for illustrative representation only and do not depict actual medical products, procedures, or outcomes. Refer to official medical guidance and product information for accurate details.
All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy’s Laboratories Ltd including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted or stored in any form without the written permission of Dr. Reddy’s.
